Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis

on behalf of the Kanto Study Group for Cell Therapy (KSGCT)

doi:10.1038/s41409-019-0689-8

Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis

on behalf of the Kanto Study Group for Cell Therapy (KSGCT)

内科学(血液)

研究成果: Letter › 査読

1 被引用数 (Scopus)

本文言語	English
ページ（範囲）	1497-1501
ページ数	5
ジャーナル	Bone Marrow Transplantation
巻	55
号	7
DOI	https://doi.org/10.1038/s41409-019-0689-8
出版ステータス	Published - 2020 7月 1

ASJC Scopus subject areas

血液学
移植

文献へのアクセス

10.1038/s41409-019-0689-8

他のファイルとリンク

引用スタイル

@article{4c4d25df79734d78a176c019680693af,

title = "Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis",

author = "{on behalf of the Kanto Study Group for Cell Therapy (KSGCT)} and Takayoshi Tachibana and Takuma Ishizaki and Satoshi Takahashi and Yuho Najima and Kimura, {Shun ichi} and Emiko Sakaida and Makoto Onizuka and Takehiko Mori and Shin Fujisawa and Fujiwara, {Shin ichiro} and Takeshi Saito and Maki Hagihara and Nobuyuki Aotsuka and Moritaka Gotoh and Kensuke Usuki and Nobuhiro Tsukada and Junya Kanda and Heiwa Kanamori and Yoshinobu Kanda and Shinichiro Okamoto",

note = "Funding Information: Conflict of interest KU reports grants and personal fees from MSD K.K., Sumitomo Dainippon Pharma, Pfizer Japan, and Celgene Corporation, grants from Astellas Pharma, Otsuka, Kyowa Kirin, Glax-oSmithKline K.K., Sanofi K.K., Shire Japan, SymBio Pharmaceuticals Limited., Daiichi Sankyo, Boehringer-Ingelheim Japan, and Janssen Pharmaceutical K.K, and personal fees from Novartis, Ono Pharmaceutical, Takeda Pharmaceuticals, Chugai Pharmaceutical, Nippon Shinyaku, and Mochida Pharmaceutical. Other authors declare that they have no conflict of interest.",

year = "2020",

month = jul,

day = "1",

doi = "10.1038/s41409-019-0689-8",

language = "English",

volume = "55",

pages = "1497--1501",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia

T2 - a KSGCT multicenter retrospective analysis

AU - on behalf of the Kanto Study Group for Cell Therapy (KSGCT)

AU - Tachibana, Takayoshi

AU - Ishizaki, Takuma

AU - Takahashi, Satoshi

AU - Najima, Yuho

AU - Kimura, Shun ichi

AU - Sakaida, Emiko

AU - Onizuka, Makoto

AU - Mori, Takehiko

AU - Fujisawa, Shin

AU - Fujiwara, Shin ichiro

AU - Saito, Takeshi

AU - Hagihara, Maki

AU - Aotsuka, Nobuyuki

AU - Gotoh, Moritaka

AU - Usuki, Kensuke

AU - Tsukada, Nobuhiro

AU - Kanda, Junya

AU - Kanamori, Heiwa

AU - Kanda, Yoshinobu

AU - Okamoto, Shinichiro

N1 - Funding Information: Conflict of interest KU reports grants and personal fees from MSD K.K., Sumitomo Dainippon Pharma, Pfizer Japan, and Celgene Corporation, grants from Astellas Pharma, Otsuka, Kyowa Kirin, Glax-oSmithKline K.K., Sanofi K.K., Shire Japan, SymBio Pharmaceuticals Limited., Daiichi Sankyo, Boehringer-Ingelheim Japan, and Janssen Pharmaceutical K.K, and personal fees from Novartis, Ono Pharmaceutical, Takeda Pharmaceuticals, Chugai Pharmaceutical, Nippon Shinyaku, and Mochida Pharmaceutical. Other authors declare that they have no conflict of interest.

PY - 2020/7/1

Y1 - 2020/7/1

UR - http://www.scopus.com/inward/record.url?scp=85073827765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073827765&partnerID=8YFLogxK

U2 - 10.1038/s41409-019-0689-8

DO - 10.1038/s41409-019-0689-8

M3 - Letter

C2 - 31537900

AN - SCOPUS:85073827765

SN - 0268-3369

VL - 55

SP - 1497

EP - 1501

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 7

ER -